Reading DNTH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DNTH free→Reading DNTH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DNTH free→QuarterlyIQ Insights · DNTH
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-7.2) + peer(0.2*3.6) + term(0.0) → -1.79% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 50 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 1 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 5, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securitie…
Results of Operations and Financial Condition Dianthus Therapeutics, Inc.’s (the “Company”) audited financial statements for the fiscal year ended December 31, 2025 are not yet available. Beginning on January 12, 2026, the Company plans to disclose in a presentation to investors (the "Presentation") that it expects to report cash, cash equivalents, and short-term investments of approximately $514 million as of December 31, 2025. A copy of the Presentation is attached as Exhibit 99.1 to this C…
Results of Operations and Financial Condition. On November 5, 2025, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…
Results of Operations and Financial Condition The information set forth below under “Preliminary Financial Information for the Three Months Ended September 30, 2025” in
Results of Operations and Financial Condition. On August 7, 2025, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Results of Operations and Financial Condition. On May 12, 2025, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Results of Operations and Financial Condition. On March 11, 2025, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securiti…